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and pulmonary dose. To prevent patient lifting, patients 
should not be pushed to perform too high amplitudes. There 
are no benefits regarding reproducibility, stability and PGW of 
changing gating method from EIG to DIBH if no visual 
guidance can be provided.  
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Purpose/Objective: For volumetric modulated arc therapy-
stereotactic body radiation therapy (VMAT-SBRT), in-
treatment four-dimensional cone-beam CT (4D CBCT) images 
are the most reliable tool for evaluating setup error and the 
intrafractional location of the moving target. We established 
and updated a novel verification system and quantitatively 
assessed the accuracy of our VMAT-SBRT delivery through the 
use of it. 
Materials and Methods: Five patients undergoing VMAT-SBRT 
at our hospital were included in this analysis. All patients had 
stage I non-small cell lung cancer or single lesion 
oligometastatic lung tumors. In the supine position, an 
abdominal compressor and the Elekta stereotactic body 
frame were used. The gross tumor volumes (GTVs) were 
contoured on all 10 phases of the 4D planning CT. GTVs were 
merged into the internal target volume (ITV). The planning 
target volume (PTV) was created by adding a 5 mm margin to 
the ITV in all directions. Fifty-five Gy in 4 fractions was 
prescribed to cover 95% of the PTV. Before each treatment, 
registration was manually performed using pre-treatment 4D 
CBCT with the Elekta XVI system, v4.5 or v5.0. During each 
fraction, in-treatment 4D CBCT images, subdivided into 10 
phases were obtained and exported to Pinnacle3. The 
respective tumor locations during beam delivery, as 
determined with the 4D CBCT, were merged to form the 
'actual ITV.' We could then evaluate discrepancies between 
the 'actual ITV' and the planning ITV. To assess the adequacy 
of the PTV margin, we also analyzed whether PTV covered 
the 'actual ITV' completely. 
 
 
 
Results: From the 5 patients, 200 4D CBCT image sets taken 
during VMAT-SBRT were successfully obtained and the 
intrafractional tumor motions during beam delivery were 
reasonably reproduced. Under suppressed respiration, the 
average amplitude of tumor motion was 4.2±3.0mm in the 
cranio-caudal direction. On average, the 'actual ITV' covered 
87.2±5.6% of the planning ITV. In addition, the respective 
PTV encompassed all tumor locations in all phases. 
Conclusions: By using in-treatment 4D CBCT, we proved the 
adequacy of our ITV-PTV margin setting for VMAT-SBRT when 
the registration for moving lung tumors was performed using 
pre-treatment 4D CBCT. This result also provides valuable 
information prior to starting adaptive SBRT for lung tumors.   
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Purpose/Objective: Internal intra-fraction motion during 
radiotherapy can result in sub-optimal treatment delivery 
and thus real-time adaptation strategies such as MLC tracking 
or gating are currently being investigated in the clinic. The 
goal of this study is to investigate the dosimetric effect of 
gated prostate cancer radiotherapy utilising kilovoltage 
intrafraction monitoring (KIM) in the first prospective clinical 
trial. In KIM, prostate position monitoring by kV flouroscopy is 
used to gate off the beam and re-position the patient if the 
prostate moves outside a predefine region. 
Materials and Methods: KIM is being evaluated for real-time 
target localisation in a 30-patient prostate radiotherapy trial. 
So far, one patient has completed the 40 fraction treatment, 
and another two patients are currently undergoing 
treatment. The dose delivered during each fraction with KIM 
was calculated using an isocenter shift dose reconstruction 
method. For the fractions where a gating event (with motion 
exceeding 3mm for 5 seconds) occurred, dose calculation was 
also performed for a simulated treatment scenario with no 
KIM gating correction. Dosimetric impact of KIM gating was 
evaluated through comparison of target and normal tissue 
dose volume statistics for the planned treatment delivery, 
delivery with KIM gating and delivery with no KIM correction 
(see Figure 1), for each of the gated fractions. 
Results: In this preliminary work, all fractions from the first 
patient’s treatment were studied. Four fractions (out of 40) 
had successful KIM gating corrections. Prostate motion (mean 
± standard deviation) with KIM corrections and simulated 
with no KIM corrections were 2.2±1.4 mm and 4.1±0.7 mm 
respectively. Ranges of differences between the planned and 
KIM corrected doses and the planned and no KIM correction 
doses were respectively: PTV D95% (-2.75, -0.26) & (-4.29, -
2.27); CTV D100% (-2.41, -0.06) & (-0.95, 0.31); rectum V65% 
(-2.30, -0.48) & (-6.09,-3.20); and bladder V65% (-0.86, 0.50) 
& (-1.02, 1.72). In these fractions, PTV V105% was higher 
than the planned value with both KIM gating (2.98-22.18%) 
and with no KIM correction (17.16-27.25%). It should be noted 
